drugset / Trial / NCT05354362
A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Timeline
- Start
- 2022-03-02
- Primary completion
- 2023-02-06
- Completion
- 2023-02-08
Outcome
Outcome not reported
Stopped (Business): “Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATG-010 | Unknown | 40 mg | — |
| Subject | ATG-010 | Unknown | 60 mg | — |
| Subject | ATG-010 | Unknown | 80 mg | — |
| Subject | ATG-010 | Unknown | 100 mg | — |
| Subject | ONATASERTIB | Small molecule | 15 mg | — |
| Subject | ONATASERTIB | Small molecule | 20 mg | — |
| Subject | ONATASERTIB | Small molecule | 30 mg | — |